Kite, A Gilead Company

This study tested an experimental one-time treatment called KTE-X19 for adults with mantle cell lymphoma, a type of blood cancer, that had returned or stopped responding to other therapies. The treatment involves collecting a patient's own immune cells, modifying them in a lab to…

This study tested whether a treatment called axicabtagene ciloleucel, a type of CAR-T cell therapy, could help people with slow-growing non-Hodgkin lymphoma that had come back or stopped responding to other treatments. It involved 159 participants whose cancer had progressed afte…

This study tested whether a personalized immune cell therapy (called axicabtagene ciloleucel or CAR-T) works better than standard second-line treatments for patients with a fast-growing type of lymphoma that has returned or not responded to initial chemotherapy. It involved 359 a…

This study tested a personalized immune cell therapy (called axicabtagene ciloleucel or CAR-T) given alongside preventive steroids to people with aggressive large B-cell lymphoma that had returned or not responded to prior treatments. The main goal was to see if giving this power…

This study tested an experimental treatment called KTE-X19, a type of CAR T-cell therapy, for adults with mantle cell lymphoma that has returned or stopped responding to other treatments. The treatment involves collecting and genetically modifying a patient's own immune cells to …